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SUMMARY
Advantages of dried blood spot include low inva-
siveness, ease and low cost of sample collection,
transport, and storage. We used tandem mass
spectrometry (LC-MS/MS) to determine pheno-
barbital levels on dried blood spot specimens and
compared this methodology to commercially
available particle enhanced turbidimetric inhibi-
tion immunoassay (PETINIA) in plasma/serum
samples. The calibration curve in matrix using
D5-phenobarbital as internal standard was linear
in the phenobarbital concentration range of
1–100 mg/L (correlation coefficient 0.9996). The
coefficients of variation in blood spots ranged
2.29–6.71% and the accuracy ranged 96.54–
103.87%. There were no significant differences
between the concentrations measured using PE-
TINA and LC-MS/MS (both had similar precision
and accuracy) however, LC-MS/MS allows at least
1.5 times higher throughput of phenobarbital anal-
ysis and additionally offers ease of sample collec-
tion which is particularly important for newborns
or small infants.
KEY WORDS: Phenobarbital, Liquid chromato-
graphy-tandem mass spectrometry, Epilepsy,
Anticonvulsant, Antiepileptic, Particle enhanced
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Phenobarbital (PB) is widely used in the treatment of
partial and generalized tonic–clonic seizures in all age
groups (Schmidt et al., 1986) and is considered a first line
drug for treating seizures and status epilepticus in the new-
born. Due to the narrow therapeutic index of the drug and
a wide interindividual variability in the rate of metabolism
and clearance, therapeutic monitoring of PB concentra-
tions has been recommended for optimizing treatment. In
the clinical setting, therapeutic PB blood concentrations
usually range from 10 to 40 mg/L (Patsalos et al., 2008).
Phenobarbital has been assayed by several analytical
techniques (Queiroz et al., 2008; Saka et al., 2008; Subra-
manian et al., 2008) but routine determinations are usu-
ally performed by particle enhanced turbidimetric
inhibition immunoassay (Tietz, 1994) or other immuno-
assay techniques (e.g., fluorescence polarisation immuno-
assays, homogeneous enzyme immunoassays). However,
analytical methods imply time consuming chromato-
graphic runs and blood sample volumes for immunoassay
methods range 0.5–2 ml, which may be a limitation in
newborns or small infants. In addition, some chromato-
graphic methods have used unspecific wavelengths for
the detection of PB. Analysis on dried blood spot (DBS)
implies lower costs in that samples can easily be sent
to the lab via mail, avoiding the costs for traveling and
personnel in charge of venipuncture; an ease of sampling
represents a major practical advantage especially in small
infants.
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Many clinical applications for the measurement of bio-
logical markers on DBS have been reported (Mei et al.,
2001), including the assay of the antiepileptic drug topira-
mate (la Marca et al., 2008), the immunosuppressive
tacrolimus (Hoogtanders et al., 2007), some antiretroviral
drugs (Koal et al., 2005) and methylene blue (Burhenne
et al., 2008).
We evaluated the use of tandem mass spectrometry
(MS/MS) to assay of PB using DBS. We demonstrated
that minimal sample preparation, high sensitivity/specific-
ity and high throughput make this method a good candi-
date for large-scale routine use.
Experimental
Materials
Phenobarbital (purity > 98%) was purchased from
Sigma-Aldrich (Steinheim, Germany); the internal
standard, Phenobarbital-D5 (99.8% D purity) was from
Cerilliant (Round Rock, TX, U.S.A). Stock solutions
(corresponding to 2,000 mg/L) of both were made in
methanol. Working solution of Phenobarbital-D5 was
0.08 mg/L. All chemicals and solvents were of the com-
mercially highest purity available.
DBS preparation
The venous blood in heparin tube was shipped on cold
packs from hospital blood collection unit to the laboratory.
Within 6 h of collection, DBS were prepared by spotting
20 ll whole blood onto Whatman 903 specimen collec-
tion paper (903, Whatman GmbH, Dassel, Germany).
Blood spots were dried for 2–3 h at room temperature.
The DBS were stored in sealed plastic bags containing
desiccant (silica pellets) and daily sent to the mass spec-
trometry laboratory. The remaining whole blood was cen-
trifuged at 620 g for 5 min to obtain serum. Sera (400 ll)
were transferred to the Dimension Vista integrated system
(Dade Behring Inc., Newark, DE, U.S.A) sample cups and
analyzed with low (10.0 mg/L), medium, (30.0 mg/L),
and high (60 mg/L) control serum samples.
Sample preparation
A pooled mixture of blood samples was spiked with PB
and 20 ll were put on filter paper from six adult healthy
volunteers after they had signed an informed consent.
Two 3.2 mm DBS (containing about 3 ll of blood
each) were punched (DBS-Puncher, 1296-071; Wallac,
Turku, Finland) and extracted in a Polypropylene 96-well
plate v-shape (Tomtec Plastics, Budapest, Hungary) with
200 ll 20/80 of water/methanol solution containing
0.08 mg/L of D5-PB. Samples were put in an orbital sha-
ker and kept at 37C for 20 min. Fifty DBS from healthy
controls and 50 spots from patients with confirmed epi-
lepsy whose PB levels had also been monitored with the
PETINIA method were tested. For all subjects, hematocrit
levels were determined using an automated Coulter coun-
ter (Beckman-Coulter ACt.8, High Wycombe, United
Kingdom).The procedure was approved by the review
board of the Meyer Children’s University-Hospital. Age
of patients and controls ranged 48 h of life-81 years (con-
trols: median 49 years, SD 15.1 years; patients: median
53 years, SD 16.8 years). DBS were stored at room tem-
perature until analysis which was on the same day of their
receipt in the laboratory. The stability of 5 and 100 mg/L
of PB on DBS were measured in triplicates during a
33 days period at room temperature, +4 and )20C, with
no significant differences being apparent. (see supplemen-
tal Table S1). The median storage time between the draw-
ing of the blood sample and the analysis was 40 h (range
2–60 h).
Methods
Particle enhanced turbidimetric inhibition
immunoassay (PETINIA)
The phenobarbital assay method is based on a particle
enhanced turbidimetric inhibition immunoassay technique
that uses a latex particle-phenobarbital reagent (PR) and
phenobarbital-specific monoclonal antibody (Ab).
Heparinized plasma/serum samples (50 healthy controls
and 50 patients) were analyzed by Petinia by using the
commercially available Dimension PHNO/Flex reagent
cartridge on an Dimension Vista integrated system (Dade
Behring Inc.). Company-provided calibrators at concen-
trations 0.0, 16.0, 32.0, 48.0, 64.0, and 80.0 mg/L were
used to establish the calibration. The analytic proce-
dure was conducted according to the manufacturer’s
instructions.
Mass spectrometry
An Applied Biosystems-Sciex (Toronto, Canada) API
4000 Triple-Quad Mass Spectrometer equipped with the
TurboIonSpray source operating under negative ion mode
at a voltage of )4,500 V was used. Declustering Potential
(DP), Collision Exit Potential (CXP) and Collision Energy
(CE) were automatically optimized for PB and D5-PB.
The resulting DP was )48 V, CE and CXP were found at
)15 and )9 V. Standard solutions of 1 lg/L of PB and
D5-PB in an aqueous solution of 80% methanol were
infused at 5 lL/min by connecting the infusion pump
directly to the source.
Quantitation was achieved by use of a Series 1100 Agi-
lent Technologies (Waldbronn, Germany) CapPump and
Micro ALS autosampler. Liquid chromatography was per-
formed using a Phenomenex Synergi 4u Fusion-RP 80A
4 lm, 2 · 150 mm chromatographic column (Phenome-
nex Italia, Anzola Emilia, Italy). Column flow was
0.2 ml/min using an aqueous solution of 80% methanol.
Column eluent was directed to the TurboIonSpray probe
without split ratio.
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Two lL of the extracted sample were injected for the
LC-MS/MS experiments. Phenobarbital concentrations
were measured by, and compared to the PETINIA tech-
nique.
Statistical procedures
The two methods were compared by use of the Bland–
Altman plot (Bland & Altman, 1986) and by linear
correlation.
Results
Results are summarized in Fig. 1 and in Table 1. Sup-
plemental Fig. S1 shows the MS/MS spectrum obtained
by fragmenting the precursor ion [231.2 Th] of PB and
D5-PB [236.2 Th] and a blank DBS, PB standard in water
and a typical patient sample. The ion-pair transition for
the quantitative experiment (SRM) is 231.2 > 188.1 for
PB and 236.2 > 193.1 for D5-PB. Supplemental Fig. S2
shows an extract ion chromatogram from DBS of a patient
with 12.1 mg/L of PB versus a PB standard solution in
water at the concentration of 12 mg/L (IS 0.08 mg/L) and
a control. No interferences or quenching of the intensity of
the signal were revealed, indicating that the assay perfor-
mances are independent from the sample matrix. Addi-
tionally, the combined effects of the components of the
sample on the measurement of the analyte, do not seem to
affect the MS response, owing to the sample dilution rate
(30 times) and the isotopic dilution strategy. The choice of
a water/methanol 20:80 solution for extraction purposes
from DBS was made considering the chromatographic
column conditions. The chromatographic conditions were
set up in order to speed-up the running time (4 min) since
specificity is provided by the MS/MS measurement. Sam-
ple dilution rate (3–3.4 lL diluted to 200 lL) and injec-
tion volume (2 lL) were selected in order to avoid
overloading the chromatographic column. No deteriora-
tion in column efficiency was observed after the analysis
of 200 DBS samples.
The calibrators, containing the internal standard at
0.08 mg/L, were at concentrations of 0, 1, 2, 5, 10, 20, 50
and 100 mg/L. For spiking studies, we evaluated linearity
by analyzing supplemented 3.2 mm DBS prepared at 0, 1,
A
C D
B
Figure 1.
LC-MS/MS versus Petinia: (A) and (C) adjusted for measured haematocrit. (B) and (D) adjusted for theoretical hae-
matocrit (40% in adults; 55% in newborns). The dashed line is the lineof identity, and the solid line is the regression line.
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2, 5, 10, 20, 50 and 100 mg/L. Intra- and inter-day impre-
cision data are reported in Table 1.
With the proposed parameters, the estimated limit of
detection (signal to noise ratio >5) in DBS was 17 lg/L
(0.5 mg/L, 30-times diluted), the limit of quantitation
(signal to noise ratio >10) was 34 lg/L (1 mg/L, 30-times
diluted).
Mean hematocrit levels for adult patients (43/50) (age:
mean and median 53 years; SD: 16.82 years) were 39.6%
(median 40%; SD: 4%); for adult controls (43/50) (age:
mean 49 years; median 50 years; SD: 12.12 years) were
38.3% (median 39.1%; SD: 4.6%). Mean hematocrit lev-
els for newborns (7/50) (age: <1 month) were 53.8%
(median: 53.8%; SD: 1.7%); for newborn controls (7/50)
(age: <1 month of life) were 55.6% (median: 55.4%; SD:
2.5%).
Discussion
We observed a significant inverse correlation between
levels of PB in plasma and in whole blood levels, owing to
the influence of hematocrit on plasma/whole-blood distri-
bution of PB. Considering this, all samples’ value obtained
from DBS were multiplied by the factor 100/(100-HCT
value) and compared to values obtained from the
PETINIA method. Linear correlation analysis and Bland/
Altman tests (summarized in Fig. 1A and 1C) showed an
optimal agreement between the two methods. Correlation
coefficient was >0.995 and the mean difference (PETINIA
minus LC-MS/MS) was +0.89 mg/L (error 4.66%) with
95% limits of agreement of Bland and Altman )1.45 mg/
L + 3.23 mg/L. All differences lie between the mean
difference €2 SD.
An objective of this new micromethod is to demon-
strate its suitability for paediatric applications and poten-
tially for domiciliary therapeutic drug monitoring.
Therefore, assuming an hematocrit range between 50–
60% (mean 55%) in newborns and 35–50% (mean 40%)
in adults we also converted the PB measurements from
DBS to plasma concentration multiplying by the factor
100/(100–55) and by factor 100/(100–40) for newborns
(up to 1 month of life) and adults. Results showed an
acceptable correlation (R = 0.979) and a good agreement
(Fig. 1B and 1D). Considering the mean difference
€2 SD, only two values exceeded limits of agreement.
They corresponded to PB values obtained from two
patients (two 58 years old males) exhibiting hematocrit
levels of 27% (this patient had undergone hemodialysis in
the last 24 h) and 49%. The large statistical difference of
these values in comparison with the applied theoretical
value (40%, see above) might explain these data. Results
in these two patients demonstrate that assay from remotely
collected DBS has limitations if hematoctrit levels are far
removed from normal. Ignoring this limitation could lead
to serious error in drug level determinations compared
with plasma.
Therapeutic monitoring of PB is essential for optimiz-
ing patient management. Monitoring of the drug from a
simple DBS that can be obtained even at home is greatly
advantageous compared with venipuncture especially in
small children.
The present LC-M-MS assay and PETINIA are both
sufficiently precise and accurate for routine TDM of PB.
Moreover, there was a good agreement between DBS con-
centration and PETINIA plasma concentration when cor-
rected for haematocrit (both actual and theoretical). The
greatest advantage of the new micromethod is an ease
sampling and transport, as well as easy sample prepara-
tion. The potential for reduction of costs should also be
considered. It is conceivable that a prick of a finger for
DBS can be performed at home. We observed that PB is
stable at room temperature for at least 1 month. The DBS
sample can easily be sent to the lab via mail avoiding the
costs for personnel in charge of venipuncture transporta-
tion and for traveling to the venipuncture site. The actual,
direct and indirect savings are very difficult to calculate in
that they vary in different health systems. Instrumental
analytical time is <4 min. For PETINIA assay, the instru-
ment requires 6 min to test one sample. The improvement
Table 1. Intra- and interday imprecision.
Considering all the examined samples,
discrepancies between expected and
measured values were within 6.8%. A pooled
DBS sample was processed 10 times, resulting
an intraday repeatability below 3.9% for all
values. Values better than 3.5% were obtained
in an interday repeatability test
Expected
concentration
(mg/L)
(n = 10)
Mean
(mg/L)
Standard
deviation
%
CV
%
Accuracy
Intraday
0 0 0
1 0.99 0.07 6.69 99.05
2 2.08 0.13 6.24 103.87
5 5.07 0.16 3.13 101.47
10 9.86 0.34 3.48 98.62
20 20.43 0.60 2.92 102.15
50 50.12 1.26 2.52 100.24
100 99.86 2.29 2.29 99.86
Interday (10 days)
0 0 0
1 0.97 0.04 4.20 97.34
2 2.03 0.09 4.63 101.31
5 5.03 0.23 4.53 100.61
10 9.65 0.32 3.33 96.54
20 19.42 1.30 6.71 97.12
50 51.54 2.53 4.91 103.08
100 99.38 4.57 4.60 99.38
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achieved in terms of throughput is at least 1.5 times if the
new LC-MS/MS method is used.
The LC-MS/MS assay from DBS is well suited for
pediatric applications and, potentially, for domiciliary
therapeutic drug monitoring.
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